HER2 Support Group Forums - View Single Post

Lani · 02-12-2011, 08:11 PM

Cyberknife was invented by a neurosurgeon at Stanford and Stanford has been at the forefront of using Cyberknife technology for tumors other than brain tumors and brain mets. Esther was only one of many who have had tumors outside the brain treated there--they are constantly seeking to treat other tumors where pinpoint accuracy is required to avoid injuring adjacent structures.

From Stanford website:

History of Stanford CyberKnife
The original CyberKnife was developed at Stanford by John Adler, MD, where the first patient was treated in 1994.

The prototype unit was used between 1994 and 2001. The CyberKnife was approved by the FDA (U.S. Food and Drug Administration) in 2001, and the first FDA approved CyberKnife was installed at Stanford in October, 2001. Stanford opened its second CyberKnife in October of 2006 (the first institution in the world to have two CyberKnife units in operation).

The 1,000th CyberKnife patient at Stanford was treated in October 2003.

The 2,000th CyberKnife patient was treated in November 2005.

The 3,500th CyberKnife patient was treated in 2007.
The 4,500th CyberKnife patient was treated in September 2009
View a video on CyberKnife Frameless Stereotactic Radiosurgery and an interview with neurosurgeon Steven Chang, MD.

^^^

CyberKnife Frameless Stereotactic Radiosurgery
VIDEO

CyberKnife - Precise Radiation Treatment

view full-size video

The CyberKnife was invented at Stanford and is considered a major advance in the radiological treatment of cancer.

This device is commonly used for treatment of tumors in the brain or the base of the skull. Physicians at the Stanford Cancer Center also have experience using the CyberKnife to treat cancers of the pancreas, prostate and lungs.

With more experience than anyone in the world using the CyberKnife to deliver stereotactic radiosurgery, the Stanford CyberKnife Treatment Center is able to provide cutting-edge radiotherapy treatment for a wider variety of cancers than any other center.

CyberKnife stereotactic radiosurgery uses computer technology that allows doctors to deliver radiation with unprecedented precision, and without uncomfortable screws or frames that were previously used to immobilize patients during treatment.
^^^^^
CyberKnife Treatment
The CyberKnife is commonly used for treatment of tumors in the brain or the base of the skull. Stanford physicians also have experience using the device to treat cancers of the pancreas, prostate and lungs.

With more experience than anyone in the world using the CyberKnife to deliver stereotactic radiosurgery, the Stanford CyberKnife Treatment Center is able to provide cutting-edge radiotherapy treatment for a wider variety of cancers than any other center.

Click here to watch a video on Brain Tumors and Cerebrovascular Diseases by Dr. Steven D. Chang.

CyberKnife is used to treat the following tumors or lesions:

Arteriovenous malformation (AVM)
View a video of arteriovenous malformation and Stanford
Acoustic Neuroma
Acoustic Neuroma Support Group at Stanford
Astrocytoma/Glioma/GBM
Chordoma
Craniopharyngioma
Hemangioblastoma
Liver
Lung
Lung Cancer Clinical Trial
Meningioma
Metastatic Tumor
Brain Metastasis Clinical Trial
Nasopharynx
Oligodendroglioma / Medulloblastoma
Other Benign Tumors
Other Primary Tumors
Pancreas
Pituitary Adenoma (Cushing's Disease)
Prostate
Schwannoma
Spine
Click here to watch a video on Spinal Disorders by Dr. Stefan A. Mindea
Trigeminal Neuralgia
Trigeminal Neuralgia Clinical Trial

^^^^
and from WWW.businesswire.com:
STANFORD, Calif. - (Business Wire) When Lori Brownell's first tumor appeared − on her left carotid artery − it was surgically removed, leaving an inches-long incision to heal. It was eight years before the feeling returned to that side of her neck, and for a time, she couldn't drive because she couldn't turn her head far enough.

On September 15, at the Stanford Cancer Center, a tumor on Brownell's right vagus nerve was the target, not of a scalpel, but of narrow, finely-focused beams of radiation. Instead of risking incisional surgery that might have affected Brownell's ability to swallow and speak, Stanford physicians decided to use a radiation machine called the CyberKnife.

And Brownell became Stanford's 5,000th CyberKnife patient − that's 5 percent of all treatments conducted since 1994, when Stanford Hospital became the first to buy and use the groundbreaking device, the brainchild of a Stanford physician.

Now, 206 health care centers worldwide have a CyberKnife, but Stanford is one of just four facilities to own two.

Once it was called Adler's Folly, a name that reflected the audacity of its inventor, Stanford neurosurgeon John Adler. Adler had imagined something that would send radiation into the body in a way that no other could do, combining computer imaging and robotic motion to treat the most difficult cancers in the brain, lung and spine, where there is no leeway for error.

A decade of development later, the folly was recognized as a treatment powerhouse, its use expanding rapidly. Brownell's tumors are benign, but genetics seem to be contributing to their occurrence. She had a second tumor, on her left jugular vein, treated with a five week course of fractionated radiotherapy two years ago. When the third appeared, her hometown neurosurgeon in Florida recommended Stanford's Griff Harsh, MD, who worked with radiation oncologist Scott Soltys, MD, to complete Brownell's treatment with the CyberKnife.

The CyberKnife, Harsh said, “not only vastly improved the safety and efficacy of irradiating many brain tumors, but also revolutionized much of radiation oncology. Our 5,000 patients, and almost 100,000 worldwide, have truly benefitted from this kind of innovative patient care.”

This use of radiation has come to be known as stereotactic radiosurgery and radiotherapy.

The CyberKnife's special quality is that it tracks tumor movement whether from breathing or other patient motion. Its beam delivery arm reacts with minute precision to real-time images of the tumor. No radiation is sent out when the tumor moves out of the beam, protecting healthy tissue that can sometimes be damaged as it might be in traditional wide field beam delivery. With lung cancer, treatment is particularly challenging because tumors move with each and every 12 breaths a minute. The CyberKnife's tracking system adjusts delivery to react to that normal, active breathing pattern.

The radiation is so highly focused it is safer to deliver a higher dose of radiation, which improves the odds that the DNA of abnormal cells will be irreversibly damaged. So scrambled, as Brownell put it, that they will die and not regrow.

Brownell was relieved to know that, unlike the five-days-a-week, five weeks long radiation she endured for her second tumor, the CyberKnife treatment would last less than an hour. She's already signed up to run marathons in November and December. “That first radiation just wiped me out,” she said. “After this, I can keep running.”

Knowing that the CyberKnife had been developed at Stanford, she said, gave her even more confidence.

As the CyberKnife's treatment repertoire of lung, liver and pancreatic cancer broadens, Stanford physicians are creating other applications that have shown good results. “The Stanford CyberKnife Program has been at the leading edge of clinical applications since the inception of the CyberKnife,” said Stanford radiation oncologist Iris C. Gibbs, MD, Co-Director of Stanford's CyberKnife Program. “Our program has expanded the uses of radiosurgery not only within the brain, but throughout the body, for a lengthening list of conditions such as vascular abnormalities; tumors, including acoustic neuroma and glomus types; and pain syndromes like trigeminal neuralgia.”

Most recently, Stanford CyberKnife protocols for treatment of patients with glomus tumors, trigeminal neuralgia and skull base tumors have shown excellent results, said Richard T. Hoppe, MD, Stanford's Chair of Radiation Oncology. The CyberKnife has also been used very successfully at Stanford as a post-operative treatment that avoids the side effects of whole brain radiation, he said. “We believe the Stanford CyberKnife Program's experience is unmatched − and that that experience raises the likelihood of improved safety and outcomes for our patients.”

Neurosurgeon Steven D. Chang, MD, is the CyberKnife Program's other co-director. He also leads the Stanford Neuromolecular Innovation Program. “The successful treatment of our 5,000th patient on the Stanford CyberKnife system confirms the clinical benefit for our patients and others elsewhere. We proudly celebrate this milestone with all of our patients, treatment team members and referring physicians. And we look forward to the Stanford CyberKnife Program continuing its role as a worldwide leader in the treatment and advancement of stereotactic radiosurgery and radiotherapy.”

About Stanford Hospital & Clinics

Stanford Hospital & Clinics is known worldwide for advanced treatment of complex disorders in areas such as cardiovascular care, cancer treatment, neurosciences, surgery, and organ transplants. Consistently ranked among the top institutions in the U.S. News & World Report annual list of “America's Best Hospitals,” Stanford Hospital & Clinics is internationally recognized for translating medical breakthroughs into the care of patients. It is part of the Stanford University Medical Center, along with the Stanford University School of Medicine and Lucile Packard Children's Hospital at Stanford. For more information, visit http://stanfordmedicine.org.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/...574〈=en

02-12-2011, 08:11 PM	#14
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	Re: Cyberknife for liver mets? Cyberknife was invented by a neurosurgeon at Stanford and Stanford has been at the forefront of using Cyberknife technology for tumors other than brain tumors and brain mets. Esther was only one of many who have had tumors outside the brain treated there--they are constantly seeking to treat other tumors where pinpoint accuracy is required to avoid injuring adjacent structures. From Stanford website: History of Stanford CyberKnife The original CyberKnife was developed at Stanford by John Adler, MD, where the first patient was treated in 1994. The prototype unit was used between 1994 and 2001. The CyberKnife was approved by the FDA (U.S. Food and Drug Administration) in 2001, and the first FDA approved CyberKnife was installed at Stanford in October, 2001. Stanford opened its second CyberKnife in October of 2006 (the first institution in the world to have two CyberKnife units in operation). The 1,000th CyberKnife patient at Stanford was treated in October 2003. The 2,000th CyberKnife patient was treated in November 2005. The 3,500th CyberKnife patient was treated in 2007. The 4,500th CyberKnife patient was treated in September 2009 View a video on CyberKnife Frameless Stereotactic Radiosurgery and an interview with neurosurgeon Steven Chang, MD. ^^^ CyberKnife Frameless Stereotactic Radiosurgery VIDEO CyberKnife - Precise Radiation Treatment view full-size video The CyberKnife was invented at Stanford and is considered a major advance in the radiological treatment of cancer. This device is commonly used for treatment of tumors in the brain or the base of the skull. Physicians at the Stanford Cancer Center also have experience using the CyberKnife to treat cancers of the pancreas, prostate and lungs. With more experience than anyone in the world using the CyberKnife to deliver stereotactic radiosurgery, the Stanford CyberKnife Treatment Center is able to provide cutting-edge radiotherapy treatment for a wider variety of cancers than any other center. CyberKnife stereotactic radiosurgery uses computer technology that allows doctors to deliver radiation with unprecedented precision, and without uncomfortable screws or frames that were previously used to immobilize patients during treatment. ^^^^^ CyberKnife Treatment The CyberKnife is commonly used for treatment of tumors in the brain or the base of the skull. Stanford physicians also have experience using the device to treat cancers of the pancreas, prostate and lungs. With more experience than anyone in the world using the CyberKnife to deliver stereotactic radiosurgery, the Stanford CyberKnife Treatment Center is able to provide cutting-edge radiotherapy treatment for a wider variety of cancers than any other center. Click here to watch a video on Brain Tumors and Cerebrovascular Diseases by Dr. Steven D. Chang. CyberKnife is used to treat the following tumors or lesions: Arteriovenous malformation (AVM) View a video of arteriovenous malformation and Stanford Acoustic Neuroma Acoustic Neuroma Support Group at Stanford Astrocytoma/Glioma/GBM Chordoma Craniopharyngioma Hemangioblastoma Liver Lung Lung Cancer Clinical Trial Meningioma Metastatic Tumor Brain Metastasis Clinical Trial Nasopharynx Oligodendroglioma / Medulloblastoma Other Benign Tumors Other Primary Tumors Pancreas Pituitary Adenoma (Cushing's Disease) Prostate Schwannoma Spine Click here to watch a video on Spinal Disorders by Dr. Stefan A. Mindea Trigeminal Neuralgia Trigeminal Neuralgia Clinical Trial ^^^^ and from WWW.businesswire.com: STANFORD, Calif. - (Business Wire) When Lori Brownell's first tumor appeared − on her left carotid artery − it was surgically removed, leaving an inches-long incision to heal. It was eight years before the feeling returned to that side of her neck, and for a time, she couldn't drive because she couldn't turn her head far enough. On September 15, at the Stanford Cancer Center, a tumor on Brownell's right vagus nerve was the target, not of a scalpel, but of narrow, finely-focused beams of radiation. Instead of risking incisional surgery that might have affected Brownell's ability to swallow and speak, Stanford physicians decided to use a radiation machine called the CyberKnife. And Brownell became Stanford's 5,000th CyberKnife patient − that's 5 percent of all treatments conducted since 1994, when Stanford Hospital became the first to buy and use the groundbreaking device, the brainchild of a Stanford physician. Now, 206 health care centers worldwide have a CyberKnife, but Stanford is one of just four facilities to own two. Once it was called Adler's Folly, a name that reflected the audacity of its inventor, Stanford neurosurgeon John Adler. Adler had imagined something that would send radiation into the body in a way that no other could do, combining computer imaging and robotic motion to treat the most difficult cancers in the brain, lung and spine, where there is no leeway for error. A decade of development later, the folly was recognized as a treatment powerhouse, its use expanding rapidly. Brownell's tumors are benign, but genetics seem to be contributing to their occurrence. She had a second tumor, on her left jugular vein, treated with a five week course of fractionated radiotherapy two years ago. When the third appeared, her hometown neurosurgeon in Florida recommended Stanford's Griff Harsh, MD, who worked with radiation oncologist Scott Soltys, MD, to complete Brownell's treatment with the CyberKnife. The CyberKnife, Harsh said, “not only vastly improved the safety and efficacy of irradiating many brain tumors, but also revolutionized much of radiation oncology. Our 5,000 patients, and almost 100,000 worldwide, have truly benefitted from this kind of innovative patient care.” This use of radiation has come to be known as stereotactic radiosurgery and radiotherapy. The CyberKnife's special quality is that it tracks tumor movement whether from breathing or other patient motion. Its beam delivery arm reacts with minute precision to real-time images of the tumor. No radiation is sent out when the tumor moves out of the beam, protecting healthy tissue that can sometimes be damaged as it might be in traditional wide field beam delivery. With lung cancer, treatment is particularly challenging because tumors move with each and every 12 breaths a minute. The CyberKnife's tracking system adjusts delivery to react to that normal, active breathing pattern. The radiation is so highly focused it is safer to deliver a higher dose of radiation, which improves the odds that the DNA of abnormal cells will be irreversibly damaged. So scrambled, as Brownell put it, that they will die and not regrow. Brownell was relieved to know that, unlike the five-days-a-week, five weeks long radiation she endured for her second tumor, the CyberKnife treatment would last less than an hour. She's already signed up to run marathons in November and December. “That first radiation just wiped me out,” she said. “After this, I can keep running.” Knowing that the CyberKnife had been developed at Stanford, she said, gave her even more confidence. As the CyberKnife's treatment repertoire of lung, liver and pancreatic cancer broadens, Stanford physicians are creating other applications that have shown good results. “The Stanford CyberKnife Program has been at the leading edge of clinical applications since the inception of the CyberKnife,” said Stanford radiation oncologist Iris C. Gibbs, MD, Co-Director of Stanford's CyberKnife Program. “Our program has expanded the uses of radiosurgery not only within the brain, but throughout the body, for a lengthening list of conditions such as vascular abnormalities; tumors, including acoustic neuroma and glomus types; and pain syndromes like trigeminal neuralgia.” Most recently, Stanford CyberKnife protocols for treatment of patients with glomus tumors, trigeminal neuralgia and skull base tumors have shown excellent results, said Richard T. Hoppe, MD, Stanford's Chair of Radiation Oncology. The CyberKnife has also been used very successfully at Stanford as a post-operative treatment that avoids the side effects of whole brain radiation, he said. “We believe the Stanford CyberKnife Program's experience is unmatched − and that that experience raises the likelihood of improved safety and outcomes for our patients.” Neurosurgeon Steven D. Chang, MD, is the CyberKnife Program's other co-director. He also leads the Stanford Neuromolecular Innovation Program. “The successful treatment of our 5,000th patient on the Stanford CyberKnife system confirms the clinical benefit for our patients and others elsewhere. We proudly celebrate this milestone with all of our patients, treatment team members and referring physicians. And we look forward to the Stanford CyberKnife Program continuing its role as a worldwide leader in the treatment and advancement of stereotactic radiosurgery and radiotherapy.” About Stanford Hospital & Clinics Stanford Hospital & Clinics is known worldwide for advanced treatment of complex disorders in areas such as cardiovascular care, cancer treatment, neurosciences, surgery, and organ transplants. Consistently ranked among the top institutions in the U.S. News & World Report annual list of “America's Best Hospitals,” Stanford Hospital & Clinics is internationally recognized for translating medical breakthroughs into the care of patients. It is part of the Stanford University Medical Center, along with the Stanford University School of Medicine and Lucile Packard Children's Hospital at Stanford. For more information, visit http://stanfordmedicine.org. Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/...574〈=en